Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Colorectal Disease
Erschienen in: International Journal of Colorectal Disease 11/2011

01.11.2011 | Original Article

Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience

verfasst von: Gianluca Rizzo, Alessandro Armuzzi, Daniela Pugliese, Alessandro Verbo, Alfredo Papa, Claudio Mattana, Gian Lodovico Rapaccini, Luisa Guidi, Claudio Coco

Erschienen in: International Journal of Colorectal Disease | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of preoperative use of TNF-alpha inhibitors on postoperative complications in patients with inflammatory bowel disease (IBD) undergoing abdominal surgery is controversial. The aim of this study was to evaluate the 30-day postoperative outcomes for IBD patients treated with these drugs prior to surgery.

Methods

We analyzed retrospectively the incidence of short-term postoperative complications. Statistical analyses were performed to reveal the independent variables that influenced postoperative complications and the role of preoperative medical therapy with anti-TNF drugs within 12 weeks prior to surgery.

Results

One hundred fourteen patients (76 with Crohn's disease (CD) and 38 ulcerative colitis (UC)) underwent abdominal surgery for IBD. Fifty-four patients were treated with anti-TNF-alpha within 12 weeks prior to surgery (anti-TNF group). Postoperative mortality and morbidity were 0% and 21%, respectively. The infection rate was 15%. A significantly higher incidence of postoperative complications was found in patients treated with high-dose steroids (58% vs. 17%; p = 0.003) after univariate analysis. The infection rate was significantly higher in patients treated with high-dose corticosteroids (50% vs. 11%; p = 0.002) and concomitant anti-TNF-alpha (60% vs. 13%; p = 0.023). Multivariate analysis revealed that only therapy with high-dose corticosteroids was significantly associated with cumulative (p = 0.017) and infective postoperative complications (p = 0.046). No significant differences were found between the anti-TNF group and the control group.

Conclusion

High-dose corticosteroids increased the risk of short-term postoperative cumulative and infective complications. Anti-TNF drugs within 12 weeks prior to abdominal surgery in patients with IBD did not appear to increase the rate of postoperative complications.
Literatur
1.
Dignass A, Van Assche G, Lindsay JO et al (2010) The second European evidenced-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4:28–62PubMedCrossRef
2.
Peyrin-Biroulet L, Deltenre P, de Suray N et al (2008) Efficacy and safety of anti-tumor necrosis factor agents in Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6:644–653PubMedCrossRef
3.
Orlando A, Armuzzi A, Papi C, The Italian Society of Gastroenterology (SIGE) and The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) et al (2011) Clinical Practice Guideline: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 43:1–20PubMedCrossRef
4.
D’Haens G, Baert F, Van Assche G, Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371:660–667PubMedCrossRef
5.
Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362:1383–1395PubMedCrossRef
6.
Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A (2008) Infliximab in Crohn's disease: early and long-term treatment. Dig Liver Dis 40(Suppl 2):S271–S279PubMedCrossRef
7.
Travis SPL, Stange EF, Lemann L et al (2008) European evidenced-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2:24–62CrossRef
8.
Rutgeerts P, Sandborn WJ, Feagan B et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 233:2462–2473CrossRef
9.
D'Haens G, Sandborn WJ, Feagan BG et al (2007) Clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132:763–786PubMedCrossRef
10.
Järnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811PubMedCrossRef
11.
Kohn A, Daperno M, Armuzzi A et al (2007) Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 26:747–756PubMedCrossRef
12.
Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878–883PubMedCrossRef
13.
Marchal L, D'Haens G, Van Assche G et al (2004) The risk of postoperative complications associated with Infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 19:749–754PubMedCrossRef
14.
Brzezinski A, Armstrong l, De Real GA et al (2002) Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn’s disease. Gastroenterology 122:A617
15.
Kasparek MS, Bruckmeier A, Beigel F, et al (2010) Effect of infliximab on postoperative complications in patients with Crohn ‘s disease undergoing abdominal surgery. Abstract DDW
16.
Selvasekar CR, Cima RR, Larson DW et al (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962PubMedCrossRef
17.
Mor IJ, Vogel JD, da Luz Moreira A et al (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51(8):1202–1207PubMedCrossRef
18.
Schluender SJ, Ippoliti A, Dubinsky M et al (2007) Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 50(11):1747–1753. doi:10.​1007/​s10350-007-9008-3 PubMedCrossRef
19.
Ferrante M, D'Hoore A, Vermeire S et al (2009) Corticosteroids but not Infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 15(7):1062–1070PubMedCrossRef
20.
Kunitake H, Hodin R, Shellito PC et al (2008) Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 12:1730–1736PubMedCrossRef
21.
Bordeianou L, Kunitake H, Shellito P et al (2010) Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis 25(3):401–404PubMedCrossRef
22.
Coquet-Reinier B, Berdah SV, Grimaud JC, et al (2010) Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc
23.
Cornillie F, Shealy D, D’Haens G et al (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15:463–473PubMedCrossRef
24.
Nestorov I (2005) Clinical pharmacokinetics of TNF antagonist: how do they differ? Sem Art Rheum
25.
Taylor PC (2010) Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 10:308–315PubMedCrossRef
26.
Appau KA, Fazio VW, Shen B et al (2008) Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg 12:1738–1744PubMedCrossRef
27.
Yang Z, Wu Q, Wu K et al (2010) Meta-analysis: pre-operative infliximab treatment on short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 31(4):486–492PubMedCrossRef
28.
Blonski W, Osterman MT, Lin MV, et al (2010) Risk of postoperative infections in IBD patients treated with perioperative anti-TNF therapy: a meta-analysis. Abstract DDW
29.
Stuck AE, Minder CE, Frey FJ et al (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963PubMedCrossRef
30.
Reding R, Michel LA, Donckier J et al (1990) Surgery in patients on long term steroid therapy: a tentative model for risks assessment. Br J Surg 77:1175–1178PubMedCrossRef
31.
Post S, Betzler M, von Ditfurth B, Schürmann G et al (1991) Risks of intestinal anastomoses in Crohn’s disease. Ann Surg 213(1):37–42PubMedCrossRef
32.
Yamamoto T, Allan RN, Keighley MR et al (2000) Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum 43:1141–1145PubMedCrossRef
33.
Alves A, Panis Y, Bouhnik Y et al (2007) Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn’s disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 50(3):331–336PubMedCrossRef
34.
Heyvaert G, Penninckx F, Filez L et al (1994) Restorative proctocolectomy in elective and emergency cases of ulcerative colitis. Int J Colorectal Dis 9(2):73–76PubMedCrossRef
35.
Tjandra JJ, Fazio VW, Milsom JW et al (1993) Omission of temporary diversion in restorative proctocolectomy—is it safe? Dis Colon Rectum 36(11):1007–1014PubMedCrossRef
36.
Lake JP, Firoozmand E, Kang JC et al (2004) Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest 8(5):547–551CrossRef
37.
Mahadevan U, Loftus EV Jr, Tremaine WJ et al (2002) Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 8(5):311–316PubMedCrossRef
38.
Aberra FN, Lewis JD, Hass D et al (2003) Corticosteroids and Immunomodulators: postoperative infectious complications risk in inflammatory bowel disease patients. Gastroenterology 125:320–327PubMedCrossRef
39.
Ziv Y, Church JM, Fazio VW et al (1996) Effect of systemic steroids on ileal pouch-anal anastomosis in patients with ulcerative colitis. Dis Colon Rectum 39:504–508PubMedCrossRef
40.
Page MJ, Poritz LS, Kunselman SJ et al (2002) Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg 6:606–613PubMedCrossRef
41.
Bruewer M, Utech M, Rijcjen EJ et al (2003) Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohn’s disease. World J Surg 27:1306–1310PubMedCrossRef
42.
Subramanian V, Saxena S, Kang JY et al (2008) Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 103:2373–2381PubMedCrossRef
Metadaten
Titel
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience
verfasst von
Gianluca Rizzo
Alessandro Armuzzi
Daniela Pugliese
Alessandro Verbo
Alfredo Papa
Claudio Mattana
Gian Lodovico Rapaccini
Luisa Guidi
Claudio Coco
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 11/2011
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-011-1236-2

Weitere Artikel der Ausgabe 11/2011

International Journal of Colorectal Disease 11/2011 Zur Ausgabe

Letter to the Editor

STARR and the older surgeon: what makes the difference?

Review

Laparoscopic versus conventional open surgery for immune function in patients with colorectal cancer

Original Article

Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn’s disease: preliminary report

Original Article

Diagnostic accuracy of C-reactive protein and white blood cell counts in the early detection of inflammatory complications after open resection of colorectal cancer: a retrospective study of 1,187 patients

Original Article

Impact of adrenomedullin on dextran sulfate sodium-induced inflammatory colitis in mice: insights from in vitro and in vivo experimental studies

Letter to the Editor

NLR as predictor: a concern in laboratory medicine aspect

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.